MARVEN

Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy (MARVEN Study)

Objective

The objective is to prospectively study nonischemic cardiomyopathy patients qualified for CRT-D following currently approved standard indications in order to:    

• Validate the MADIT-CRT- derived model predicting fast VT/VF in Nonischemic cardiomyopathy patients with QRS>120 ms
• Determine whether CMR added to the risk model validated in specific aim 1 will further improve risk stratification for predicting fast VT/VF in Nonischemic cardiomyopathy patients with QRS>120 ms
• Evaluate costs of risk stratification using Holter and CMR in relationship to costs of implanted devices without risk stratification

Eligibility

• Optimal pharmacologic therapy as defined by published guidelines from the American Heart Association and the American College of Cardiology for at least 3 calendar months after NICM diagnosis
• Nonischemic dilated cardiomyopathy meeting current primary prevention indications for CRT-D:
  • QRS ≥ 120 ms for LBBB patients with NYHA class II, III or IV (ambulatory), OR
  • QRS ≥ 120 ms for non-LBBB patients with NYHA class III or IV (ambulatory), OR
  • QRS ≥ 150 ms for non-LBBB patients with NYHA class II
  As evidenced by ECG qualifying patient for CRT-D implant within 12 calendar months prior to consent
• LVEF ≤ 35% within 12 calendar months prior to or on consent date by angiographic, cardiac nuclear test, CMR or echocardiographic methods
• Sinus rhythm by most recent ECG qualifying patient for CRT-D implant